Cholangiocarcinoma

A Comprehensive Genomic Profiling Study Comparing Primary Tumor, Metastatic Tumor Tissue, and Liquid Biopsy in Patients with Intrahepatic CCA

Cholangiocarcinoma

2020 Year in Review: Cholangiocarcinoma — December 18, 2020

Results of a comprehensive genomic profiling study indicate differences in genomic alterations detected from primary tumor, metastatic tumor tissue, and liquid biopsy in patients with intrahepatic CCA; IDH1 and FGFR2 genomic alterations are detectable in liquid biopsy, with potential practice-changing implications in clinical practice.

Phase 3 ClarIDHy Study: Pharmacokinetics and Pharmacodynamics of Ivosidenib in Patients with Mutant IDH1 Advanced CCA

Cholangiocarcinoma

2020 Year in Review: Cholangiocarcinoma — December 18, 2020

Results of the PK/PD analysis of the ClarIDHy study showed that the study dose of the IDH1 inhibitor ivosidenib resulted in good exposure and inhibition of oncometabolite D-2-HG.

In Patients with Advanced or Metastatic CCA and FGFR2 Fusions, Retrospective Analysis of Post–Second-Line Chemotherapy Outcomes

Cholangiocarcinoma

2020 Year in Review: Cholangiocarcinoma — December 18, 2020

Results of the retrospective analysis of phase 2 study of the FGFR1-3 selective tyrosine kinase inhibitor infigratinib indicate that efficacy outcomes in patients with CCA and FGFR2 fusions were better with third- or later-line infigratinib therapy compared with standard second-line chemotherapy.

Adjuvant Concurrent Chemoradiotherapy in Patients with Extrahepatic CCA

Cholangiocarcinoma

2020 Year in Review: Cholangiocarcinoma — December 18, 2020

Retrospective analysis data indicate that adjuvant chemoradiotherapy was associated with improved survival compared with chemotherapy alone in patients with extrahepatic CCA.

Biomarker Analysis in a Phase 2 Study of Infigratinib (BGJ398) for CCA with FGFR2 Fusions

Cholangiocarcinoma

2020 Year in Review: Cholangiocarcinoma — December 17, 2020

Comprehensive genomic profiling of tumor tissue and cfDNA of patients enrolled in the phase 2 study of infigratinib underscored the heterogeneity of CCA and the potential clinical utility of cfDNA to identify FGFR2 fusions.

IDH1 Mutation Detection in ctDNA and Association with Clinical Response in Patients with Advanced iCCA from Phase 3 ClarIDHy

Cholangiocarcinoma

Web Exclusives — May 30, 2020

Detection of IDH1 mutations in plasma from patients with intrahepatic cholangiocarcinoma is highly concordant with detection in tumor tissue.

Retrospective Analysis of Post Second-Line Chemotherapy Outcomes with Advanced or Metastatic CCA and FGFR2 Fusions

Cholangiocarcinoma

Web Exclusives — May 28, 2020

In a phase 2 trial of patients with cholangiocarcinoma and FGFR2 fusions, infigratinib administered as third- and later-line chemotherapy treatment resulted in a meaningful progression-free survival and objective response rate benefit.

Natural History of Fibroblast Growth Factor Receptor–Altered Cholangiocarcinoma

Cholangiocarcinoma

Web Exclusives — May 28, 2020

The clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations are reported based on a retrospective chart review.

Primary Tumor versus Metastatic Tumor Tissue versus Liquid Biopsy in iCCA: A Comparative Comprehensive Genomic Profiling Study

Cholangiocarcinoma

Web Exclusives — May 28, 2020

Liquid biopsies may offer the opportunity to obtain information regarding specific genetic mutations in intrahepatic cholangiocarcinoma.

Surgery for Cholangiocarcinoma

Cholangiocarcinoma

Web Exclusives — February 21, 2020

At the First Annual Cholangiocarcinoma Summit, presenters discussed recent advances in the management of patients with cholangiocarcinoma (CCA).